全文获取类型
收费全文 | 613篇 |
免费 | 31篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 38篇 |
妇产科学 | 1篇 |
基础医学 | 76篇 |
口腔科学 | 17篇 |
临床医学 | 71篇 |
内科学 | 110篇 |
皮肤病学 | 20篇 |
神经病学 | 59篇 |
特种医学 | 121篇 |
外科学 | 36篇 |
综合类 | 12篇 |
预防医学 | 33篇 |
眼科学 | 1篇 |
药学 | 34篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 14篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 7篇 |
2016年 | 8篇 |
2015年 | 13篇 |
2014年 | 14篇 |
2013年 | 20篇 |
2012年 | 9篇 |
2011年 | 16篇 |
2010年 | 34篇 |
2009年 | 37篇 |
2008年 | 14篇 |
2007年 | 27篇 |
2006年 | 19篇 |
2005年 | 22篇 |
2004年 | 18篇 |
2003年 | 10篇 |
2002年 | 15篇 |
2001年 | 16篇 |
2000年 | 11篇 |
1999年 | 10篇 |
1998年 | 35篇 |
1997年 | 37篇 |
1996年 | 30篇 |
1995年 | 29篇 |
1994年 | 11篇 |
1993年 | 19篇 |
1992年 | 3篇 |
1991年 | 6篇 |
1990年 | 11篇 |
1989年 | 13篇 |
1988年 | 19篇 |
1987年 | 15篇 |
1986年 | 9篇 |
1985年 | 12篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 12篇 |
1981年 | 5篇 |
1980年 | 9篇 |
1978年 | 7篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1957年 | 1篇 |
1953年 | 1篇 |
排序方式: 共有665条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Polycystic kidney disease is an autosomal dominant disease that may be associated with cystic disease of the liver. In women, the cysts may develop early and be more troublesome than in men. Cystadenocarcinoma of the pancreas is uncommon, comprising 1% of primary pancreatic malignancies. This case report is the first to describe a familial association between polycystic kidney disease and cystadenocarcinoma of the pancreas and liver in the English medical literature. A patient with autosomal dominant polycystic kidney disease (ADPKD) and multiple hepatic cysts developed cystadenocarcinoma of the pancreas with multiple malignant liver cysts. The patient's mother, sister, and niece had ADPKD, and the patient's sister also died of pancreatic cystadenocarcinoma. We believe that the development of these two disease entities in which the primary pathology is cyst formation has a genetic association. (Gastroenterology 1997 Jun;112(6):2104-7) 相似文献
5.
The aim of the double-blind, placebo-controlled study was to investigate the effects of a continuous combined estrogen-progestogen treatment (Climodien, Lafamme) as compared with estrogen alone on vigilance in insomniac postmenopausal syndrome patients, objectified by EEG mapping. METHODS: In a 3-arm, 2-month parallel group design phase, patients received a combination of estradiol valerate 2 mg and the novel progestogen dienogest 3 mg (Climodien 2/3) or estradiol valerate 2 mg alone or placebo. In a subsequent open-label phase, all patients received estradiol valerate 2 mg+dienogest 2 mg (Climodien 2/2). EEG mapping was carried out before and after the 2-month double-blind phase as well as after the 2-month open-label treatment. RESULTS: As compared with placebo, Climodien 2/3 induced a marked and highly significant increase in absolute power in all frequency bands, specifically in alpha-2 activity. Moreover, a significant increase in relative alpha-2 power, a decrease in relative delta and beta power as well as an acceleration of the dominant frequency and of the delta and alpha centroids suggested a marked improvement in vigilance. In contrast, under estradiol valerate 2 mg alone, only a slight augmentation of alpha and attenuation of relative delta and beta power occurred, suggesting only a slight vigilance improvement as compared with placebo. Thus, dienogest 2 mg increased the estrogen effect, which was also confirmed by a statistical evaluation of the differences between Climodien 2/3 and estradiol valerate alone (augmentation of alpha-2, attenuation of relative beta, acceleration of the dominant frequency). Moreover, Climodien 2/2 also markedly increased alpha-2 power, decreased relative beta-2 power and accelerated the alpha centroid. Finally, comparing Climodien 2/3 with Climodien 2/2, there was even a dose-efficacy relation. CONCLUSIONS: Estradiol valerate 2 mg improves vigilance slightly, thereby confirming previous findings. The additional administration of dienogest does not minimize the effect of estrogen, but on the contrary increases it, which makes the combination superior to both placebo and estradiol valerate alone. Vigilance improvement may be of great therapeutic benefit to menopausal syndrome patients at a time when increased adaptability is needed to adjust to increasing sexual, marital, occupational and social difficulties known to occur specifically in this period of life. 相似文献
6.
7.
8.
Annika?E?StenbergEmail author Lisskulla?Sylvén Carl?GM?Magnusson Malou?Hultcrantz 《Journal of negative results in biomedicine》2004,3(1):6
Disturbances in the immune system has been described in Turner syndrome, with an association to low levels of IgG and IgM
and decreased levels of T- and B-lymphocytes. Also different autoimmune diseases have been connected to Turner syndrome (45,
X), thyroiditis being the most common. 相似文献
9.
A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy 总被引:3,自引:4,他引:3
Milasin J; Muntoni F; Severini GM; Bartoloni L; Vatta M; Krajinovic M; Mateddu A; Angelini C; Camerini F; Falaschi A; Mestroni L; Giacca M 《Human molecular genetics》1996,5(1):73-79
X-linked dilated cardiomyopathy (XLDC) is a familial heart disease
presenting in young males as a rapidly progressive congestive heart
failure, without clinical signs of skeletal myopathy. This condition has
recently been linked to the dystrophin gene in some families and deletions
encompassing the genomic region coding for the first muscle exon have been
detected. In order to identify the defect responsible for this disease at
the molecular level and to understand the reasons for the selective heart
involvement, a family with a severe form of XLDC was studied. In the
affected members, no deletions of the dystrophin gene were observed.
Analysis of the muscle promoter, first exon and intron regions revealed the
presence of a single point mutation at the first exon-intron boundary,
inactivating the universally conserved 5' splice site consensus sequence of
the first intron. This mutation introduced a new restriction site for MseI,
which cosegregates with the disease in the analyzed family. Expression of
the major dystrophin mRNA isoforms (from the muscle-, brain- and Purkinje
cell-promoters) was completely abolished in the myocardium, while the
brain- and Purkinje cell- (but not the muscle-) isoforms were detectable in
the skeletal muscle. Immunocytochemical studies with anti- dystrophin
antibodies showed that the protein was reduced in quantity but normally
distributed in the skeletal muscle, while it was undetectable in the
cardiac muscle. These findings indicate that expression of the muscle
dystrophin isoform is critical for myocardial function and suggest that
selective heart involvement in dystrophin- linked dilated cardiomyopathy is
related to the absence, in the heart, of a compensatory expression of
dystrophin from alternative promoters.
相似文献